Distribution of company announcements to the professional platforms, finance portals and syndication of important corporate news to a wide variety of news aggregators and financial news systems.
Active Biotech (STO:ACTI) - Laquinimod -- positive data presented from extension study
- 57-57 -- Clinical Phase II/III trial to commence in 2009
- RhuDex® -- Additional preclinical tests under way
- ANYARA -- Phase III study proceeding as planned
- TASQ -- Phase II study proceeding as planned
- Net sales SEK 8.8 M (8.7)
- Operating loss SEK 167.0 M (loss: 147.8 )
- Loss after tax SEK 162.0 M (loss: 152.0)
- Loss per share for the period amounted to SEK 3.30 (loss: 3.30) For further information, please contact: Tomas Leanderson President and CEO Tel: +46 (0)46-19 20 95
Göran Forsberg VP Investor Relations & Business Development Tel: +46 (0)46-19 11 54
Hans Kolam CFO Tel: +46 (0)46-19 20 44
Active Biotech AB (Corp. Reg. No. 556223-9227) PO Box 724, SE-220 07 Lund Tel: +46 (0)46-19 20 00 Fax: +46 (0)46-19 11 00
This report is also available at www.activebiotech.com
This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
